Open Access. Powered by Scholars. Published by Universities.®
Hematology/Oncology and Stem Cell Therapy
Allogeneic stem cell transplantation; Chronic lymphocytic leukemia; Outcome analysis; Predictors of outcomes
Articles 1 - 1 of 1
Full-Text Articles in Cancer Biology
Outcomes Of Patients Diagnosed With Chronic Lymphocytic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results From A Tertiary Care Center, Swe Mar Linn, Ram Vasudevan Nampoothiri, Carol Chen, Ivan Pasic, Zeyad Al-Shaibani, Wilson Lam, Arjun Datt Law, Fotios V. Michelis, Dennis D.H. Kim, Armin Gerbitz, Jeffrey Lipton, Rajat Kumar, Jonas Mattsson, Auro Viswabandya
Outcomes Of Patients Diagnosed With Chronic Lymphocytic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results From A Tertiary Care Center, Swe Mar Linn, Ram Vasudevan Nampoothiri, Carol Chen, Ivan Pasic, Zeyad Al-Shaibani, Wilson Lam, Arjun Datt Law, Fotios V. Michelis, Dennis D.H. Kim, Armin Gerbitz, Jeffrey Lipton, Rajat Kumar, Jonas Mattsson, Auro Viswabandya
Hematology/Oncology and Stem Cell Therapy
Background: Allogeneic hematopoietic stem cell transplantation (allo-HCT) is currently the only curative treatment for patients with chronic lymphocytic leukemia (CLL). Methods: We analyzed the outcomes of 93 patients (median age: 52 years) who underwent allo-HCT at our center between 1989 and 2019. Results: After a median follow-up of 35 months, relapse was observed in 15.1% (n = 14) patients. The estimated 2-year non-relapse mortality, relapse-free survival, and overall survival (OS) were 38.1%, 54.2%, and 58.7%, respectively. The ECOG performance status 2 (hazard ratio [HR]: 4.1; p = .001) and use of total body irradiation (in a myeloablative conditioning regimen; HR: …